TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4 to $4.5.
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the price target from $4 to $4.5.